Abstract 17355: Obesity is Strongly Associated With New Onset Atrial Fibrillation/Flutter in Middle-Aged Adults
Introduction: Obesity has been found to be associated with new onset atrial fibrillation/flutter (AF) in several prospective cohort and case control studies. However, the strength of association is not well established, especially in middle-aged and younger adults.
Hypothesis: Obesity will be independently associated with new onset AF in a national cohort of middle-aged, privately-insured individuals.
Methods: We performed a longitudinal cohort study from January 1, 2006 through December 31, 2013 using a national claims database that tracks all inpatient, outpatient and pharmacy claims data. Obese and non-obese individuals without a diagnosis of AF were recruited 1:1 during an observation period from January 1, 2005 through December 31, 2005 if they maintained continuous enrollment over the duration of the study period. The primary endpoint was new diagnosis of AF. Logistic regression was used to determine the strength of association between obesity and new onset AF controlling for age, gender, hypertension and diabetes.
Results: A total of 67,278 individuals were included in the cohort, divided evenly between those with and without a diagnosis of obesity. The average age and sex of each cohort was 43.8 years and 76.9% female. Obese individuals were significantly more likely to have hypertension (29.5% vs 14.6%) and diabetes (12.7% vs 5.2%) at study onset. Over 8 years of follow up a new diagnosis of AF was recorded in 1,511 (2.2%) individuals. Obesity was strongly associated with a new diagnosis of AF after controlling for age, gender, hypertension and diabetes (OR 1.4; 95% CI: 1.3-1.6).
Conclusions: Obesity is strongly associated with new onset AF in middle-aged adults. This information contributes to the growing evidence supporting the causal relationship between obesity and AF and could promote novel strategies for AF prevention and treatment.
Author Disclosures: A. Foy: None. J. Mandrola: Honoraria; Modest; Medtronic. G. Naccarelli: Consultant/Advisory Board; Significant; Janssen, Pfizer, Boehringer-Ingelheim, Daiichi Sankyo, GlaxoSmithKline, Astra Zeneca.
- © 2016 by American Heart Association, Inc.